Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Corcept Therapeutics revenue
Corcept Therapeutics's revenue is $675.0 million.
What is Corcept Therapeutics's revenue?
- Corcept Therapeutics's revenue growth from 2012 to 2024 is 20,312.46%.
- Corcept Therapeutics has 238 employees, and the revenue per employee ratio is $2,836,302.
- Corcept Therapeutics's peak quarterly revenue was $182.5M in 2024(q3).
- Corcept Therapeutics peak revenue was $675.0M in 2024.
- Corcept Therapeutics annual revenue for 2023 was 482.4M, 20.04% growth from 2022.
- Corcept Therapeutics annual revenue for 2024 was 675.0M, 39.94% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Corcept Therapeutics historical revenue
Corcept Therapeutics's peak revenue was $675.0M in 2024. The peak quarterly revenue was $182.5M in 2024(q3).
Corcept Therapeutics's revenue increased from $3.3m in 2012 to $675.0M currently. That's a 20,312.46% change in annual revenue.
Corcept Therapeutics annual revenue
Corcept Therapeutics annual revenue over time
| Fiscal year / year | Corcept Therapeutics revenue |
|---|---|
| 2012 | $3.3M |
| 2013 | $10.4M |
| 2014 | $26.6M |
| 2015 | $50.3M |
| 2016 | $81.3M |
| 2017 | $159.2M |
| 2018 | $251.2M |
| 2019 | $306.5M |
| 2020 | $353.9M |
| 2021 | $366.0M |
| 2022 | $401.9M |
| 2023 | $482.4M |
| 2024 | $675.0M |
Rate Corcept Therapeutics' financial transparency
Corcept Therapeutics annual growth
Corcept Therapeutics saw the greatest revenue growth in 2013, when revenue increased by 213.18%.
Corcept Therapeutics had the lowest revenue growth in 2021, when revenue changed by 3.42%.
Corcept Therapeutics annual growth rate over time
| Year | Corcept Therapeutics growth |
|---|---|
| 2013 | 213%↑ |
| 2014 | 156%↑ |
| 2015 | 89%↑ |
| 2016 | 62%↑ |
| 2017 | 96%↑ |
| 2018 | 58%↑ |
| 2019 | 22%↑ |
| 2020 | 15%↑ |
| 2021 | 3%↑ |
| 2022 | 10%↑ |
| 2023 | 20%↑ |
| 2024 | 40%↑ |
Corcept Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Corcept Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | $875,000 | $1.1M | $1.4M |
| 2013 | $1.7M | $1.9M | $2.6M | $4.1M |
| 2014 | $4.4M | $5.9M | $7.3M | $9.0M |
| 2015 | $10.1M | $12.0M | $13.3M | $15.0M |
| 2016 | $16.1M | $19.7M | $21.7M | $23.8M |
| 2017 | $27.6M | $35.6M | $42.8M | $53.3M |
| 2018 | $57.7M | $62.3M | $64.4M | $66.8M |
| 2019 | $64.8M | $72.3M | $81.5M | $87.9M |
| 2020 | $93.2M | $88.6M | $86.3M | $85.7M |
| 2021 | $79.4M | $91.6M | $96.1M | $98.8M |
| 2022 | $93.7M | $103.4M | $101.7M | $103.1M |
| 2023 | $105.7M | $117.7M | $123.6M | $135.4M |
| 2024 | $146.8M | $163.8M | $182.5M | $181.9M |
Corcept Therapeutics jobs nearby
Do you work at Corcept Therapeutics?
Is Corcept Therapeutics transparent about its revenue structure?
Corcept Therapeutics financial information
| CEO | Joseph K. Belanoff M.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 238 |
| Date Founded | 1998 |
| Headquarters | Menlo Park, California |
| Number of Locations | 2 |
| Revenue | $675.0M |
| Net Income | $101,418,000 |
| Gross Proft | $664.2M (2024) |
| PE Ratio | 8.20 |
| Tax Rate | 0.1% |
| Market Capitalization | $1.2B |
| Total Assets | $583,430,000 |
| Ticker | CORT |
Corcept Therapeutics jobs you might like
Corcept Therapeutics financing
Corcept Therapeutics received early financing of $28.0M on 2001-05-01.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $28M | 05/2001 |
| Series Unknown | $12.8M | 12/2002 |
| Post Ipo Equity | $3M | 11/2006 |
| Post Ipo Equity | $10.1M | 08/2007 |
| Post Ipo Equity | $18M | 10/2009 |
| Post Ipo Equity | $7.7M | 04/2010 |
| Post Ipo Equity | $525K | 04/2012 |
Corcept Therapeutics investors
| Investors | Security type |
|---|---|
| Sutter Hill Ventures | Post Ipo Equity |
| Paperboy Ventures LLC | Post Ipo Equity |
| Alta Partners | Post Ipo Equity |
| Sutter Hill Ventures | Post Ipo Equity |
| Longitude Capital | Post Ipo Equity |
| Alta Partners | Post Ipo Equity |
Corcept Therapeutics competitors
Corcept Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Corcept Therapeutics's smallest competitor is Acorda Therapeutics with revenue of $117.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 256 |
| Merck | $90,328 | $64.2B | 74,000 | 2,121 |
| Upsher-Smith Laboratories | $63,937 | $420.0M | 550 | 33 |
| Medivation | $94,135 | $1.0B | 628 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 614 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Seagen | $85,008 | $2.0B | 900 | - |
| Ligand Pharmaceuticals | $82,001 | $241.5M | 116 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 37 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Corcept Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Corcept Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Corcept Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Corcept Therapeutics. The data presented on this page does not represent the view of Corcept Therapeutics and its employees or that of Zippia.
Corcept Therapeutics may also be known as or be related to CORCEPT THERAPEUTICS INC, Corcept Therapeutics, Corcept Therapeutics Inc., Corcept Therapeutics Incorporated and Corcept Therapeutics, Inc.